“Spesolimab Improves Quality of Life in Generalized Pustular Psoriasis (GPP) as Measured by Proportion of Patients With Dermatology Life Quality Index (DLQI) Scores of 0 or 1 and Reduction in Pain Severity Over Time: Results From the EFFISAYIL® 2 Trial” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s652. doi:10.25251/fmm5fj59.